Seroconversion after COVID-19 vaccination and heart transplant recipients: Correspondence.

Dear Editor,

We would like to share ideas on the publication “High rate of seroconversion after COVID‐19 vaccination during the long‐term follow‐up of heart transplant recipients (HTRs).” Ambrosi et al. reported that HTR getting up to four vaccine doses and a relatively low intensity immunosuppressive medication, without evidence of inadequate treatment, may achieve a significant level of seroconversion after COVID‐19 vaccination. However, it is crucial to take into account any confounding variables that can affect the immunological characteristics discovered. It is also possible that a COVID occurred before to the immunization, altering subsequent immunity. Asymptomatic COVID‐19 infection is typically not unusual. In the absence of any symptoms, a history of infection cannot completely exclude past COVID‐19, and the results can be misleading. Before the current immunological investigation, the asymptomatic COVID‐19 might manifest at any time, either prior to immunization or during the time between two doses of the vaccine. Even while it would not be enough to rule out COVID‐19 in the absence of symptoms, a history of infection is typically required for an accurate assessment of a vaccine's effectiveness.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

FUNDING INFORMATION

The authors received no specific funding for this work.